NCT04357860View on ClinicalTrials.gov

Clinical Trial of Sarilumab in Adults With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

March 9, 2021

Study Completion Date

April 6, 2021

Conditions
SARS-CoV 2SARS
Interventions
DRUG

Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]

Best available treatment up to 14 days plus Sarilumab 200 mg

DRUG

Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]

Best available treatment up to 14 days plus Sarilumab 400 mg

DRUG

Best available treatment

Best available treatment up to 14 days

Trial Locations (1)

14004

Hospital Universitario Reina Sofía, Córdoba

Sponsors
All Listed Sponsors
collaborator

Junta de Andalucia

OTHER_GOV

collaborator

Red Andaluza de Ensayos Clínicos en Enfermedades Infecciosas (Red ANCRAID)

UNKNOWN

lead

Maimónides Biomedical Research Institute of Córdoba

OTHER